Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Change in Accured Expenses (2020 - 2025)

SAB Biotherapeutics' Change in Accured Expenses history spans 6 years, with the latest figure at -$394856.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 72.58% year-over-year to -$394856.0; the TTM value through Dec 2025 reached $941524.0, up 176.48%, while the annual FY2025 figure was $941524.0, 176.48% up from the prior year.
  • Change in Accured Expenses reached -$394856.0 in Q4 2025 per SABSW's latest filing, down from -$287490.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.0 million in Q1 2021 to a low of -$2.0 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is -$57878.8, with a median of -$303860.5 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 22512.85% in 2021, then crashed 265.24% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $276329.0 in 2021, then plummeted by 215.89% to -$320231.0 in 2022, then skyrocketed by 538.06% to $1.4 million in 2023, then crashed by 202.66% to -$1.4 million in 2024, then skyrocketed by 72.58% to -$394856.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Change in Accured Expenses are -$394856.0 (Q4 2025), -$287490.0 (Q3 2025), and $1.0 million (Q2 2025).